Stage 3 NSCLC has a distinct clinical profile from metastatic (Stage 4) disease and has different treatment goals5-7
~24% of patients with NSCLC present with Stage 3 disease8
~82% of patients with Stage 3 NSCLC have unresected disease9*
Treatment with curative intent concurrent chemoradiotherapy is given to patients and offers patients additional treatment options in the unresectable Stage 3 NSCLC setting10
“Stage 3 lung cancer is a curative intent disease. So we should maximize [the] chance of a cure and minimize toxicity using the tools we discussed today.”
NSCLC=non-small cell lung cancer; CRT=chemoradiotherapy.
*Unresected disease includes patients with unresectable disease and patients with resectable disease who declined surgical intervention.
†The views and opinions expressed in the Art of CRT video series are those of the individual panel members and do not represent the views or opinions of AstraZeneca. These videos contain anecdotal information gathered from a discussion with 8 physicians and nurses based on their opinions/experiences. Recommendations are general and may vary with patients.